<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433678</url>
  </required_header>
  <id_info>
    <org_study_id>1972</org_study_id>
    <nct_id>NCT02433678</nct_id>
  </id_info>
  <brief_title>An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin</brief_title>
  <official_title>An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaleida Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, prospective, randomized, placebo -controlled, parallel design and
      double blind study to evaluate oxidative stress, inflammation and hypertension markers and
      mediators before and after treatment with dapagliflozin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two groups of 26 patients each (total 52 patients) with type 2 diabetes on oral agents will
      be included in the study. One group will be randomized to dapagliflozin (a dose of 5 mg daily
      will be titrated to 10 mg daily during the first week) while the other will be placebo. The
      patients will be treated for 12 weeks. Only half the patients (equal numbers in both groups)
      will be tested for the secondary endpoints related to postprandial and single dose induced
      changes. The primary endpoint of the study is to detect a significant difference in the
      percent change in fasting Nuclear factor-k B (NFκB) activation (DNA binding activity) in
      mononuclear cells (MNC) before and after dapagliflozin use (0 week vs. 12 weeks) as compared
      to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the Percent Change in Fasting Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells Activation (DNA Binding Activity) in Mononuclear Cells Before and After Dapagliflozin Use</measure>
    <time_frame>12 weeks</time_frame>
    <description>nuclear factor kappa-light-chain-enhancer of activated B cells measurement through Transcription factor assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Expression of Inflammatory Mediators</measure>
    <time_frame>12 Weeks</time_frame>
    <description>p47phox in mononuclear cells through real time polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Expression of Inflammatory Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Suppressor Of Cytokine Signaling 3 measurement in Mononuclear cells through real time polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Expression of Inflammatory Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Interleukin 1 Beta measurement in mononuclear cells through real time polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Expression of Inflammatory Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>c-Jun N-terminal kinase 1 measurement in Mononuclear cells through real time polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Expression of Inflammatory Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Toll-like receptor 4 measurement in mononuclear cells through real time polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Expression of Inflammatory Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Tumor necrosis factor alpha measurement in mononuclear through real time polymerase chain reaction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Hypertension Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma concentrations measurement of Angiotensinogen through enzyme-linked immunosorbent assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hypertension Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma concentration measurement of Angitosensin II through enzyme-linked immunosorbent assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hypertension Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma concentration measurement of Renin through enzyme-linked immunosorbent assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hypertension Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma concentration measurement of Atrial natriuretic peptide through enzyme linked immunosorbent assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hypertension Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma concentration measurement of B-type natriuretic peptide through enzyme linked immunosorbent assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hypertension Mediators</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma concentration measurement of Cyclic guanosine monophosphate through enzyme linked immunosorbent assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hypertension Mediators</measure>
    <time_frame>12 week</time_frame>
    <description>Plasma concentration measurment of Cyclic adenosine monophosphate through enzyme linked immunosorbent assay</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be treated for 12 weeks with placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg daily for the 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-80 years inclusive.

          -  Type 2 diabetes

          -  BMI ≥30 kg/m2

          -  Subjects on statins, ACE inhibitors, ARBs, thiazolidinediones and -antioxidants will
             be allowed as long as they are on stable doses of these -compounds and the dosage in
             not changed during the course of study. -Patients will be evenly distributed between
             the 2 groups based on statins, -ARBs, TZDs and ACE inhibitors use.

          -  HbA1c ≤ 8.0%

        Exclusion Criteria:

          -  Use of GLP-1 agonists or DPP-IV or SGLT-2 inhibitors therapy in the last 3 -months.

          -  Risk for pancreatitis, i.e., history of gallstones, alcohol abuse, and
             -hypertriglyceridemia.

          -  Coronary event or procedure (myocardial infarction, unstable angina, coronary -artery
             bypass, surgery or coronary angioplasty) in the previous 3 months.

          -  Hepatic disease: Severe hepatic insufficiency and/or significant abnormal liver
             -function defined as:

          -  aspartate aminotransferase (AST) &gt;3x upper limit of normal (ULN) and/or -alanine
             aminotransferase (ALT) &gt;3x ULN

          -  Total bilirubin &gt;2.0 mg/dL (34.2 µmol/L)

          -  Positive serologic evidence of current infectious liver disease including Hepatitis B
             viral antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody

          -  (liver function tests more than 3 times the upper limit of normal)

          -  Renal impairment (serum eGFR &lt;60 ml/min)

          -  Any other life-threatening, non-cardiac disease

          -  Uncontrolled hypertension (BP &gt; 160/100 mm of Hg)

          -  Congestive Heart Failure class III or IV.

          -  Use of an investigational agent or therapeutic regimen within 30 days of study

          -  Participation in any other concurrent clinical trial

          -  pregnant or breastfeeding patients

          -  Volume depleted patients. Patients at risk for volume depletion due to co-existing
             conditions or concomitant medications, such as loop diuretics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ECMC Ambulatory Center, 3rd Floor</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <results_first_submitted>October 3, 2019</results_first_submitted>
  <results_first_submitted_qc>October 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Paresh Dandona</investigator_full_name>
    <investigator_title>distinguished professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02433678/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin</title>
          <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin</title>
          <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="10"/>
                    <measurement group_id="B2" value="61" spread="9"/>
                    <measurement group_id="B3" value="61" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in the Percent Change in Fasting Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells Activation (DNA Binding Activity) in Mononuclear Cells Before and After Dapagliflozin Use</title>
        <description>nuclear factor kappa-light-chain-enhancer of activated B cells measurement through Transcription factor assay</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 total patients in each group, 4 dropped in the placebo arm and 3 dropped in the Dapagliflozin arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Percent Change in Fasting Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells Activation (DNA Binding Activity) in Mononuclear Cells Before and After Dapagliflozin Use</title>
          <description>nuclear factor kappa-light-chain-enhancer of activated B cells measurement through Transcription factor assay</description>
          <population>Out of the 26 total patients in each group, 4 dropped in the placebo arm and 3 dropped in the Dapagliflozin arm</population>
          <units>arbitrary unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.762" spread="0.14"/>
                    <measurement group_id="O2" value="0.733" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.802" spread="0.12"/>
                    <measurement group_id="O2" value="0.835" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.776" spread="0.15"/>
                    <measurement group_id="O2" value="0.815" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Expression of Inflammatory Mediators</title>
        <description>p47phox in mononuclear cells through real time polymerase chain reaction</description>
        <time_frame>12 Weeks</time_frame>
        <population>Out of the 26 total patients in each group, 4 dropped in the placebo arm and 3 dropped in the Dapagliflozin arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Expression of Inflammatory Mediators</title>
          <description>p47phox in mononuclear cells through real time polymerase chain reaction</description>
          <population>Out of the 26 total patients in each group, 4 dropped in the placebo arm and 3 dropped in the Dapagliflozin arm</population>
          <units>arbitrary unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="0"/>
                    <measurement group_id="O2" value="100" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="14"/>
                    <measurement group_id="O2" value="104" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Expression of Inflammatory Mediators</title>
        <description>Suppressor Of Cytokine Signaling 3 measurement in Mononuclear cells through real time polymerase chain reaction</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Expression of Inflammatory Mediators</title>
          <description>Suppressor Of Cytokine Signaling 3 measurement in Mononuclear cells through real time polymerase chain reaction</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>arbitrary unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.20"/>
                    <measurement group_id="O2" value="0.60" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.19"/>
                    <measurement group_id="O2" value="0.66" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Expression of Inflammatory Mediators</title>
        <description>Interleukin 1 Beta measurement in mononuclear cells through real time polymerase chain reaction</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Expression of Inflammatory Mediators</title>
          <description>Interleukin 1 Beta measurement in mononuclear cells through real time polymerase chain reaction</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>arbitrary unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.697" spread="0.21"/>
                    <measurement group_id="O2" value="0.756" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.705" spread="0.21"/>
                    <measurement group_id="O2" value="0.741" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Expression of Inflammatory Mediators</title>
        <description>c-Jun N-terminal kinase 1 measurement in Mononuclear cells through real time polymerase chain reaction</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Expression of Inflammatory Mediators</title>
          <description>c-Jun N-terminal kinase 1 measurement in Mononuclear cells through real time polymerase chain reaction</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>arbitrary unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.802" spread="0.19"/>
                    <measurement group_id="O2" value="0.856" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.810" spread="0.21"/>
                    <measurement group_id="O2" value="0.820" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Expression of Inflammatory Mediators</title>
        <description>Toll-like receptor 4 measurement in mononuclear cells through real time polymerase chain reaction</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Expression of Inflammatory Mediators</title>
          <description>Toll-like receptor 4 measurement in mononuclear cells through real time polymerase chain reaction</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>arbitrary unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.704" spread="0.15"/>
                    <measurement group_id="O2" value="0.774" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.708" spread="0.17"/>
                    <measurement group_id="O2" value="0.731" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Expression of Inflammatory Mediators</title>
        <description>Tumor necrosis factor alpha measurement in mononuclear through real time polymerase chain reaction</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Expression of Inflammatory Mediators</title>
          <description>Tumor necrosis factor alpha measurement in mononuclear through real time polymerase chain reaction</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>arbitrary unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.762" spread="0.14"/>
                    <measurement group_id="O2" value="0.733" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.776" spread="0.15"/>
                    <measurement group_id="O2" value="0.815" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hypertension Mediators</title>
        <description>Plasma concentrations measurement of Angiotensinogen through enzyme-linked immunosorbent assay</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypertension Mediators</title>
          <description>Plasma concentrations measurement of Angiotensinogen through enzyme-linked immunosorbent assay</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.08" spread="0.41"/>
                    <measurement group_id="O2" value="7.23" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" spread="0.38"/>
                    <measurement group_id="O2" value="5.88" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hypertension Mediators</title>
        <description>Plasma concentration measurement of Angitosensin II through enzyme-linked immunosorbent assay</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypertension Mediators</title>
          <description>Plasma concentration measurement of Angitosensin II through enzyme-linked immunosorbent assay</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="5.5"/>
                    <measurement group_id="O2" value="29.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="5.9"/>
                    <measurement group_id="O2" value="19.6" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hypertension Mediators</title>
        <description>Plasma concentration measurement of Renin through enzyme-linked immunosorbent assay</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypertension Mediators</title>
          <description>Plasma concentration measurement of Renin through enzyme-linked immunosorbent assay</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1599" spread="492"/>
                    <measurement group_id="O2" value="1630" spread="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1632" spread="543"/>
                    <measurement group_id="O2" value="1844" spread="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hypertension Mediators</title>
        <description>Plasma concentration measurement of Atrial natriuretic peptide through enzyme linked immunosorbent assay</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypertension Mediators</title>
          <description>Plasma concentration measurement of Atrial natriuretic peptide through enzyme linked immunosorbent assay</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="12"/>
                    <measurement group_id="O2" value="92" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" spread="18"/>
                    <measurement group_id="O2" value="125" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hypertension Mediators</title>
        <description>Plasma concentration measurement of B-type natriuretic peptide through enzyme linked immunosorbent assay</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypertension Mediators</title>
          <description>Plasma concentration measurement of B-type natriuretic peptide through enzyme linked immunosorbent assay</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" spread="12.9"/>
                    <measurement group_id="O2" value="64.7" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" spread="20.1"/>
                    <measurement group_id="O2" value="62.9" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hypertension Mediators</title>
        <description>Plasma concentration measurement of Cyclic guanosine monophosphate through enzyme linked immunosorbent assay</description>
        <time_frame>12 weeks</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypertension Mediators</title>
          <description>Plasma concentration measurement of Cyclic guanosine monophosphate through enzyme linked immunosorbent assay</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>pmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="18"/>
                    <measurement group_id="O2" value="73" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" spread="22"/>
                    <measurement group_id="O2" value="89" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hypertension Mediators</title>
        <description>Plasma concentration measurment of Cyclic adenosine monophosphate through enzyme linked immunosorbent assay</description>
        <time_frame>12 week</time_frame>
        <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypertension Mediators</title>
          <description>Plasma concentration measurment of Cyclic adenosine monophosphate through enzyme linked immunosorbent assay</description>
          <population>Out of the 26 patients in each group, 4 dropped in the placebo arm and 3 dropped in the drug arm</population>
          <units>pmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="4"/>
                    <measurement group_id="O2" value="78" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" spread="5"/>
                    <measurement group_id="O2" value="80" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients will be treated for 12 weeks with placebo once daily
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Dapagliflozin</title>
          <description>10 mg daily for the 12 weeks
dapagliflozin: SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paresh Dandona</name_or_title>
      <organization>University at Buffalo</organization>
      <phone>716-535-1850</phone>
      <email>dandona@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

